Preliminary Results from VioQuest Pharmaceuticals, Inc.’ Phase I Trial of Novel Akt Inhibitor VQD-002 in Patients with Advanced Leukemias Demonstrate Promising Clinical Activity

BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) today announced the presentation of data for VQD-002 (triciribine phosphate monohydrate), a specific inhibitor of Akt phosphorylation, at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA. Interim results from the Phase I clinical trial demonstrate that VQD-002 is well-tolerated and shows signs of clinical activity in patients with advanced leukemias.